Structures by: Chow P. S.
Total: 110
Zonisamide-2-hydroxy-5-methylpyridine
C8H8N2O3S,C6H7NO
CrystEngComm (2018) 20, 21 2923
a=14.1373(3)Å b=11.23707(18)Å c=9.45521(17)Å
α=90.00° β=106.2761(19)° γ=90.00°
Zonisamide:Caffeine
C8H8N2O3S,C8H10N4O2
CrystEngComm (2018) 20, 21 2923
a=9.59020(10)Å b=13.30840(10)Å c=14.24360(10)Å
α=90° β=91.8550(10)° γ=90°
Form II of 1:1 cocrystal of ethenzamide and gentisic acid
C9H11NO2,C7H6O4
CrystEngComm (2009) 11, 9 1823
a=7.7217(15)Å b=12.668(3)Å c=15.749(3)Å
α=90.00° β=102.44(3)° γ=90.00°
Form III of 1:1 cocrystal of ethenzamide and gentisic acid
C9H11NO2,C7H6O4
CrystEngComm (2009) 11, 9 1823
a=7.1283(14)Å b=16.242(3)Å c=12.904(3)Å
α=90.00° β=96.25(3)° γ=90.00°
Form I of 1:1 cocrystal of ethenzamide and gentisic acid
C9H11NO2,C7H6O4
CrystEngComm (2009) 11, 9 1823
a=8.0485(16)Å b=9.1139(18)Å c=22.607(5)Å
α=94.13(3)° β=91.52(3)° γ=113.94(3)°
Form I of 1:1 cocrystal of ethenzamide and saccharin
C9H11NO2,C7H5NO3S
CrystEngComm (2009) 11, 5 889
a=7.2141(14)Å b=7.4923(15)Å c=15.456(3)Å
α=85.14(3)° β=86.43(3)° γ=70.65(3)°
Form II of 1:1 cocrystal of ethenzamide and saccharin
C9H11NO2,C7H5NO3S
CrystEngComm (2009) 11, 5 889
a=8.6125(17)Å b=16.607(3)Å c=11.183(2)Å
α=90.00° β=91.45(3)° γ=90.00°
1:1 Cocrystal of nitrofurantoin and 4-hydroxybenzoic acid
C8H6N4O5,C7H6O3
CrystEngComm (2011) 13, 3 759
a=10.298(2)Å b=6.4096(13)Å c=24.680(7)Å
α=90.00° β=108.08(3)° γ=90.00°
Nitrofurantoin-pyridine(1:1)
C13H11N5O5
CrystEngComm (2013) 15, 5 878
a=8.3012(17)Å b=12.940(3)Å c=14.208(3)Å
α=111.01(3)° β=96.22(3)° γ=91.11(3)°
Nitrofurantoin and 2-Picoline(1:1)
C8H6N4O5,C6H7N
CrystEngComm (2013) 15, 5 878
a=7.0324(14)Å b=22.647(4)Å c=10.031(4)Å
α=90.00° β=112.38(2)° γ=90.00°
1:1:1 solvate of nitrofurantoin, 3-picoline and water
C8H6N4O5,C6H7N,H2O
CrystEngComm (2013) 15, 5 878
a=15.268(6)Å b=6.4161(19)Å c=8.461(3)Å
α=90.00° β=105.286(5)° γ=90.00°
Nitrofurantoin-3-picoline(1:1)
C14H13N5O5
CrystEngComm (2013) 15, 5 878
a=6.1489(12)Å b=7.4328(15)Å c=16.446(3)Å
α=85.35(3)° β=85.97(3)° γ=83.67(3)°
1:1 nitrofurantoin and 4-picoline
C8H6N4O5,C6H7N
CrystEngComm (2013) 15, 5 878
a=14.840(3)Å b=8.0152(16)Å c=12.951(3)Å
α=90.00° β=91.12(3)° γ=90.00°
1:1:1 cocrystal of nitrofurantoin, 2-pyridone and acetonitrile
C8H6N4O5,C5H5NO,C2H3N
CrystEngComm (2013) 15, 5 878
a=8.1736(16)Å b=9.3544(19)Å c=11.894(2)Å
α=103.46(3)° β=109.31(3)° γ=90.14(3)°
1:1 salt of nitrofurantoin and 4-dimethylaminopyridine
C15H16N6O5
CrystEngComm (2013) 15, 5 878
a=8.616(4)Å b=26.655(11)Å c=7.029(3)Å
α=90.00° β=100.722(9)° γ=90.00°
1:1:1 cocrystal of nitrofurantoin, 2-pyridone and acetonitrile
C8H6N4O5,C7H8N2O,C2H3N
CrystEngComm (2013) 15, 5 878
a=7.2712(15)Å b=18.918(4)Å c=15.451(4)Å
α=90.00° β=117.41(2)° γ=90.00°
2-chloro-4-nitrobenzoic acid hydrate
C7H4ClNO4,H2O
CrystEngComm (2011) 13, 3 1037
a=7.2871(15)Å b=7.9395(16)Å c=8.5516(17)Å
α=117.58(3)° β=95.80(3)° γ=93.48(3)°
1,4-dioxane solvate of 2-chloro-4-nitrobenzoic acid
C7H4ClNO4,0.5(C4H8O2)
CrystEngComm (2011) 13, 3 1037
a=6.918(3)Å b=8.368(3)Å c=9.714(3)Å
α=106.777(2)° β=93.774(4)° γ=108.433(5)°
Acetophenone solvate of 2-chloro-4-nitrobenzoic acid
C7H4ClNO4,C8H8O
CrystEngComm (2011) 13, 3 1037
a=5.8156(12)Å b=10.387(2)Å c=12.207(2)Å
α=83.67(3)° β=77.63(3)° γ=81.03(3)°
P-xylene solvate of 2-chloro-4-nitrobenzoic acid
C8H10,2(C7H4ClNO4)
CrystEngComm (2011) 13, 3 1037
a=10.790(2)Å b=11.767(2)Å c=8.9666(18)Å
α=90.00° β=90.71(3)° γ=90.00°
Mesitylene solvate of 2-chloro-4-nitrobenzoic acid
C9H12,2(C7H4ClNO4)
CrystEngComm (2011) 13, 3 1037
a=23.088(5)Å b=12.018(2)Å c=8.9206(18)Å
α=90.00° β=110.29(3)° γ=90.00°
Sulfamerazine-1,4-dioxane (1:1)
C15H20N4O4S
CrystEngComm (2012) 14, 2 691
a=11.511(2)Å b=12.436(3)Å c=12.095(2)Å
α=90.00° β=102.05(3)° γ=90.00°
Sulfamerazine-1,4-dioxane (1:0.5)
C13H16N4O3S
CrystEngComm (2012) 14, 2 691
a=7.7675(16)Å b=8.1233(16)Å c=12.631(3)Å
α=91.16(3)° β=95.69(3)° γ=105.23(3)°
Sulfamerazine-dimethylformamide(1:1)
C11H12N4O2S,C3H7NO
CrystEngComm (2012) 14, 2 691
a=9.774(2)Å b=12.556(3)Å c=14.659(3)Å
α=76.58(3)° β=77.57(3)° γ=86.18(3)°
Sulfamerazine-dimethylacetamide(1:1)
C15H21N5O3S
CrystEngComm (2012) 14, 2 691
a=7.6792(15)Å b=8.3101(17)Å c=15.125(3)Å
α=93.13(3)° β=101.81(3)° γ=104.77(3)°
Sulfamerazine-cyclopentanone(1:1)
C16H20N4O3S
CrystEngComm (2012) 14, 2 691
a=5.9650(12)Å b=9.6479(19)Å c=14.817(3)Å
α=76.16(3)° β=83.05(3)° γ=89.71(3)°
Sulfamerazine-3-Picoline(1:1)
C17H19N5O2S
CrystEngComm (2012) 14, 2 691
a=7.8319(16)Å b=8.1117(16)Å c=15.358(3)Å
α=76.47(3)° β=77.04(3)° γ=73.54(3)°
Monohydrate of Piracetam-4-hydroxybenzoic acid (1:1)
C13H18N2O6
CrystEngComm (2012) 14, 7 2381
a=6.4211(13)Å b=6.6058(13)Å c=16.590(3)Å
α=96.20(3)° β=96.76(3)° γ=90.86(3)°
MOnohydrate of caffeine-4HBA (1:1)
C15H18N4O6
CrystEngComm (2012) 14, 7 2381
a=7.2188(14)Å b=8.5282(17)Å c=13.827(3)Å
α=90.33(3)° β=101.29(3)° γ=107.57(3)°
Oxaprozin-1,2-bis(4-pyridyl)ethane
C18H15NO3,C6H6N
RSC Adv. (2016)
a=9.7069(19)Å b=10.878(2)Å c=10.907(2)Å
α=76.50(3)° β=68.03(3)° γ=66.04(3)°
Oxaprozin-Salbutamol
C13H22NO3,C18H14NO3
RSC Adv. (2016)
a=10.453(2)Å b=10.627(2)Å c=13.379(3)Å
α=76.02(3)° β=69.82(3)° γ=88.05(3)°
Oxaprozin-4,4'-Bipyridine
C18H15NO3,C5H4N
RSC Adv. (2016)
a=13.422(3)Å b=15.305(3)Å c=18.618(4)Å
α=90.00° β=103.53(3)° γ=90.00°
Oxaprozin-2-Amino-3-Picoline
C18H14NO3,C6H9N2
RSC Adv. (2016)
a=6.0156(12)Å b=8.8644(18)Å c=19.296(4)Å
α=81.31(3)° β=85.29(3)° γ=80.23(3)°
Oxaprozin-piperazine
C18H14NO3,C2H6N
RSC Adv. (2016)
a=5.8155(12)Å b=7.3355(15)Å c=19.744(4)Å
α=90.14(3)° β=91.13(3)° γ=99.08(3)°
DMSO solvate of 2-chloro-4-nitrobenzoic acid
C7H4ClNO4,C2H6OS
CrystEngComm (2011) 13, 3 1037
a=5.497(3)Å b=10.408(4)Å c=10.594(4)Å
α=74.095(15)° β=81.029(12)° γ=85.487(16)°
Oxaprozin
C18H15NO3
RSC Adv. (2016)
a=10.3129(5)Å b=7.6460(3)Å c=36.7642(15)Å
α=90.00° β=90.00° γ=90.00°
Triflusal-BA cocrystal
C10H7F3O4,C7H7NO
CrystEngComm (2015) 17, 48 9323
a=5.1765(10)Å b=15.228(3)Å c=21.041(4)Å
α=90° β=93.91(3)° γ=90°
Triflusal-Isonicotinamide cocrystal
C10H7F3O4,C6H6N2O
CrystEngComm (2015) 17, 48 9323
a=17.345(7)Å b=5.1415(17)Å c=19.447(7)Å
α=90° β=112.506(5)° γ=90°
Triflusal-2-Picoliniamide cocrystal
C10H7F3O4,C6H6N2O
CrystEngComm (2015) 17, 48 9323
a=5.5536(11)Å b=11.950(2)Å c=12.200(2)Å
α=96.01(3)° β=94.85(3)° γ=95.99(3)°
Triflusal-urea cocrystal
CH4N2O,2(C10H7F3O4)
CrystEngComm (2015) 17, 48 9323
a=14.601(3)Å b=10.920(2)Å c=15.342(3)Å
α=90° β=102.49(3)° γ=90°
Triflusal-Propionamide cocrystal
C10H7F3O4,C3H7NO
CrystEngComm (2015) 17, 48 9323
a=18.729(6)Å b=9.921(3)Å c=8.067(3)Å
α=90° β=97.605(4)° γ=90°
Triflusal-valpromide cocrystal
C10H7F3O4,C8H17NO
CrystEngComm (2015) 17, 48 9323
a=19.8545(8)Å b=5.06409(17)Å c=21.8530(11)Å
α=90° β=114.362(6)° γ=90°
1:1 ethenzamide and salicylic acid cocrystal
C9H11NO2,C7H6O3
CrystEngComm (2012) 14, 24 8515
a=10.679(2)Å b=9.6670(19)Å c=14.845(3)Å
α=90.00° β=106.97(3)° γ=90.00°
1:1 ethenzamide and vanillic acid cocrystal
C9H11NO2,C8H8O4
CrystEngComm (2012) 14, 24 8515
a=13.774(3)Å b=14.911(3)Å c=8.0828(16)Å
α=90.00° β=102.87(3)° γ=90.00°
1:1 cocrystal of ethenzamide and 2-chloro-4-nitrobenzoic acid
C9H11NO2,C7H4ClNO4
CrystEngComm (2012) 14, 24 8515
a=7.7402(15)Å b=8.3181(17)Å c=13.216(3)Å
α=76.02(3)° β=79.85(3)° γ=84.69(3)°
2:1 ethenzamide and 4-aminobenzoic acid cocrystal
2(C9H11NO2),C7H7NO2
CrystEngComm (2012) 14, 24 8515
a=9.0570(18)Å b=32.685(7)Å c=8.1857(16)Å
α=90.00° β=93.39(3)° γ=90.00°
1:1 ethenzamide and 4-hydroxybenzoic acid
C9H11NO2,C7H6O3
CrystEngComm (2012) 14, 24 8515
a=9.4871(19)Å b=6.4682(13)Å c=23.703(5)Å
α=90.00° β=98.65(3)° γ=90.00°
1:0.5 ethenzamide and fumaric acid cocrystal
C9H11NO2,0.5(C4H4O4)
CrystEngComm (2012) 14, 24 8515
a=8.2154(16)Å b=8.4654(17)Å c=9.3991(19)Å
α=70.30(3)° β=71.82(3)° γ=65.97(3)°
C21H18F3N5O4
C21H18F3N5O4
CrystEngComm (2014) 16, 26 5793
a=6.9931(14)Å b=10.127(2)Å c=15.112(3)Å
α=95.46(3)° β=96.70(3)° γ=101.17(3)°
C19H15F3N2O3
C19H15F3N2O3
CrystEngComm (2014) 16, 26 5793
a=7.5628(15)Å b=7.6450(15)Å c=14.552(3)Å
α=90.45(3)° β=92.14(3)° γ=95.81(3)°
C38H28F6N4O4
C38H28F6N4O4
CrystEngComm (2014) 16, 26 5793
a=9.827(2)Å b=10.361(2)Å c=25.005(5)Å
α=84.67(3)° β=81.34(3)° γ=71.46(3)°
C13H15N3O5
C13H15N3O5
CrystEngComm (2013) 15, 29 5877
a=7.0070(14)Å b=11.224(2)Å c=16.950(3)Å
α=90.00° β=91.95(3)° γ=90.00°
C13H15N3O5
C13H15N3O5
CrystEngComm (2013) 15, 29 5877
a=6.8143(14)Å b=22.419(5)Å c=8.8759(18)Å
α=90.00° β=101.85(3)° γ=90.00°
C16H18N6O6
C16H18N6O6
CrystEngComm (2013) 15, 29 5877
a=7.8906(16)Å b=8.7030(17)Å c=12.517(3)Å
α=90.00° β=97.84(3)° γ=90.00°
C16H18N6O6
C16H18N6O6
CrystEngComm (2013) 15, 29 5877
a=3.7036(7)Å b=7.8401(16)Å c=29.573(6)Å
α=90.00° β=90.63(3)° γ=90.00°
C16H17N5O6
C16H17N5O6
CrystEngComm (2013) 15, 29 5877
a=5.0595(10)Å b=17.246(3)Å c=19.056(4)Å
α=90.00° β=97.25(3)° γ=90.00°
C16H19N5O6
C16H19N5O6
CrystEngComm (2013) 15, 29 5877
a=5.1175(10)Å b=17.467(4)Å c=18.763(4)Å
α=90.00° β=96.71(3)° γ=90.00°
Form I cocrystal of ethenzamide with ethylmalonic acid
C9H11NO2,C5H8O4
CrystEngComm (2010) 12, 11 3691
a=7.6928(15)Å b=8.8062(18)Å c=11.575(2)Å
α=93.04(3)° β=108.70(3)° γ=91.72(3)°
Form II of ethenzamide and ethylmalonic acid cocrystal
C9H11NO2,C5H8O4
CrystEngComm (2010) 12, 11 3691
a=14.501(3)Å b=7.6438(15)Å c=14.323(3)Å
α=90.00° β=108.45(3)° γ=90.00°
Form II cocrystal of 1:1 ethenzamide and ethylmalonic acid cocrystal
C9H11NO2,C5H8O4
CrystEngComm (2010) 12, 11 3691
a=14.463(3)Å b=7.6366(15)Å c=14.296(3)Å
α=90.00° β=108.42(3)° γ=90.00°
Form 1 of 1:1 nicotinamide and pimelic acid
C7H12O4,C6H6N2O
CrystEngComm (2012) 14, 23 8193
a=5.4242(11)Å b=7.3161(15)Å c=17.917(4)Å
α=99.69(3)° β=94.01(3)° γ=103.93(3)°
Form 2 of 1:1 nicotinamide and pimelic acid
C7H12O4,C6H6N2O
CrystEngComm (2012) 14, 23 8193
a=9.290(7)Å b=31.04(2)Å c=4.981(4)Å
α=90.00° β=90.00° γ=90.00°
C15H17NO2,C6H6O2
C15H17NO2,C6H6O2
Acta Crystallographica Section B (2019) 75, 6
a=7.20150(10)Å b=12.23260(10)Å c=21.3487(3)Å
α=90° β=90° γ=90°
Polymorph of Agometaline-hydroquinone (1:1) cocrystal
C15H17NO2,C6H6O2,
Acta Crystallographica Section B (2019) 75, 6
a=7.33300(10)Å b=29.3095(4)Å c=8.80460(10)Å
α=90° β=94.7480(10)° γ=90°
C19H20ClNO6
C19H20ClNO6
Acta crystallographica Section B, Structural science, crystal engineering and materials (2014) 70, Pt 1 54-62
a=11.783(2)Å b=8.5387(17)Å c=19.297(4)Å
α=90.00° β=96.03(3)° γ=90.00°
C18H20ClNO8
C18H20ClNO8
Acta crystallographica Section B, Structural science, crystal engineering and materials (2014) 70, Pt 1 54-62
a=8.5456(17)Å b=11.740(2)Å c=19.269(4)Å
α=90.00° β=90.00° γ=90.00°
C36H39Cl2NO14
C36H39Cl2NO14
Acta crystallographica Section B, Structural science, crystal engineering and materials (2014) 70, Pt 1 54-62
a=8.6852(17)Å b=15.047(3)Å c=27.605(6)Å
α=90.00° β=90.00° γ=90.00°
C19H22ClNO8
C19H22ClNO8
Acta crystallographica Section B, Structural science, crystal engineering and materials (2014) 70, Pt 1 54-62
a=21.931(4)Å b=8.6541(17)Å c=11.797(2)Å
α=90.00° β=117.57(3)° γ=90.00°
Ethenzamide--gentisic acid--acetic acid (2/1/1)
2(C9H11NO2),C7H6O4,C2H4O2
Acta Crystallographica Section E (2010) 66, 5 o1045-o1046
a=8.8083(18)Å b=8.8802(18)Å c=19.880(4)Å
α=93.65(3)° β=93.55(3)° γ=119.45(3)°
Pyrimidin-2-amine--1-phenylcyclopentane-1-carboxylic acid (1/1)
C4H5N3,C12H14O2
Acta Crystallographica Section E (2011) 67, 3 o552-o553
a=9.1461(18)Å b=10.490(2)Å c=15.474(3)Å
α=90.00° β=98.14(3)° γ=90.00°
Nitrofurantoin methanol monosolvate
C8H6N4O5,CH4O
Acta Crystallographica Section E (2011) 67, 3 o550-o551
a=6.4084(13)Å b=6.5941(13)Å c=26.705(5)Å
α=90.00° β=91.70(3)° γ=90.00°
1:1 cocrystal of theophylline and gentisic acid
C7H8N4O2,C7H6O4
Acta Crystallographica Section E (2009) 65, 9 o2126-o2127
a=7.0989(14)Å b=8.0543(16)Å c=13.034(3)Å
α=86.08(3)° β=81.27(3)° γ=74.14(3)°
2-Aminopyridinium 1-phenylcyclopropane-1-carboxylate
C5H7N2,C10H9O2
Acta Crystallographica Section E (2010) 66, 12 o3339-o3340
a=8.6147(17)Å b=9.0555(18)Å c=9.2346(18)Å
α=75.56(3)° β=87.72(3)° γ=72.79(3)°
<i>N</i>,<i>N</i>-Dimethylpyridin-4-aminium 1-phenylcyclopentane-1-carboxylate monohydrate
C7H11N2,C12H13O2,H2O
Acta Crystallographica Section E (2011) 67, 5 o1227
a=6.1666(12)Å b=18.206(4)Å c=15.702(3)Å
α=90.00° β=97.33(3)° γ=90.00°
Haloperidol-oxalic acid dihydrate
C44H52Cl2F2N2O10
Crystal Growth & Design (2014) 14, 5 2542
a=11.961(2)Å b=12.954(3)Å c=14.825(3)Å
α=114.00(3)° β=99.25(3)° γ=90.72(3)°
ACN solvate of HAL and OA salt
C46H51Cl2F2N3O8
Crystal Growth & Design (2014) 14, 5 2542
a=13.125(3)Å b=11.996(2)Å c=26.810(5)Å
α=90.00° β=90.06(3)° γ=90.00°
Haloperidol-fumaric acid salt dihydrate
C23H29ClFNO6
Crystal Growth & Design (2014) 14, 5 2542
a=8.7151(17)Å b=10.152(2)Å c=14.454(3)Å
α=97.42(3)° β=98.87(3)° γ=114.92(3)°
Haloperidol-succinic acid salt hydrate
C23H30ClFNO6
Crystal Growth & Design (2014) 14, 5 2542
a=8.6026(17)Å b=10.585(2)Å c=13.862(3)Å
α=108.39(3)° β=101.96(3)° γ=99.31(3)°
Haloperidol-Acetic acid salt dihydrate
C23H31ClFNO6
Crystal Growth & Design (2014) 14, 5 2542
a=8.7476(17)Å b=10.374(2)Å c=13.837(3)Å
α=105.57(3)° β=100.04(3)° γ=96.10(3)°
Haloperidol-Formic acid salt
C23H27ClFNO6
Crystal Growth & Design (2014) 14, 5 2542
a=8.4958(17)Å b=10.032(2)Å c=26.324(5)Å
α=90.00° β=94.46(3)° γ=90.00°
1:1 salt of haloperidol and saccharin
C28H28ClFN2O5S
Crystal Growth & Design (2014) 14, 5 2542
a=11.189(2)Å b=19.890(4)Å c=12.562(3)Å
α=90.00° β=114.22(3)° γ=90.00°
1:1 salt of HAL and CSA
C27H36ClFN2O5S
Crystal Growth & Design (2014) 14, 5 2542
a=8.4571(17)Å b=9.768(2)Å c=17.989(4)Å
α=87.28(3)° β=86.32(3)° γ=68.48(3)°
Form II of a 1:1 salt of HAL and ACE-H
C25H28ClFN2O6S
Crystal Growth & Design (2014) 14, 5 2542
a=9.5340(19)Å b=10.120(2)Å c=14.360(3)Å
α=88.15(3)° β=83.73(3)° γ=65.69(3)°
C14H15FN4O4
C14H15FN4O4
Crystal Growth & Design (2014) 14, 12 6557
a=5.0825(10)Å b=9.7492(19)Å c=15.148(3)Å
α=77.78(3)° β=89.74(3)° γ=77.45(3)°
C14H15FN4O4
C14H15FN4O4
Crystal Growth & Design (2014) 14, 12 6557
a=5.2764(11)Å b=10.181(2)Å c=13.495(3)Å
α=87.43(3)° β=81.56(3)° γ=78.70(3)°
C15H15FN2O6
C15H15FN2O6
Crystal Growth & Design (2014) 14, 12 6557
a=5.1227(10)Å b=21.618(4)Å c=13.215(3)Å
α=90.00° β=93.39(3)° γ=90.00°
C15H19FN6O6
C15H19FN6O6
Crystal Growth & Design (2014) 14, 12 6557
a=8.4887(17)Å b=8.6643(17)Å c=12.184(2)Å
α=91.83(3)° β=100.87(3)° γ=105.30(3)°
C14H15FN2O6
C14H15FN2O6
Crystal Growth & Design (2014) 14, 12 6557
a=12.609(3)Å b=11.125(2)Å c=19.976(4)Å
α=90.00° β=92.16(3)° γ=90.00°
Metaxalone
C12H15NO3
Crystal Growth & Design (2011) 11, 9 4101
a=5.5559(11)Å b=10.321(2)Å c=19.819(4)Å
α=82.82(3)° β=88.63(3)° γ=82.49(3)°
1:1 Cocrystal of nitrofurantoin and 3-aminobenzoic acid
C8H6N4O5,C7H7NO2
Crystal Growth & Design (2012) 12, 12 5925
a=9.1485(18)Å b=9.4656(19)Å c=9.903(2)Å
α=107.39(3)° β=98.66(3)° γ=97.17(3)°
1:1 Cocrystal of nitrofurantoin and 4-aminobenzoic acid
C8H6N4O5,C7H7NO2
Crystal Growth & Design (2012) 12, 12 5925
a=6.7539(14)Å b=7.4546(15)Å c=16.032(3)Å
α=92.64(3)° β=91.81(3)° γ=102.47(3)°
Form I 1:1 cocrystal of ethenzamide and 3,5-dinitrobenzoic acid
C9H11NO2,C7H4N2O6
Crystal Growth & Design (2010) 10, 5 2229
a=7.7552(16)Å b=14.875(3)Å c=14.587(3)Å
α=90.00° β=99.28(3)° γ=90.00°
0.5 acetone solvate of 1:1 cocrystal of ethenzamide and 3,5-dinitrobenzoic acid
2(C9H11NO2),2(C7H4N2O6),C3H6O
Crystal Growth & Design (2010) 10, 5 2229
a=7.6784(15)Å b=8.1720(16)Å c=15.642(3)Å
α=103.82(3)° β=91.93(3)° γ=100.39(3)°
0.5 dioxane solvate of 1:1 cocrystal of ethenzamide and 3,5-dinitrobenzoic acid
C9H11NO2,C7H4N2O6,0.5(C4H8O2)
Crystal Growth & Design (2010) 10, 5 2229
a=7.6623(15)Å b=8.3247(17)Å c=15.362(3)Å
α=99.74(3)° β=91.75(3)° γ=102.04(3)°
0.5 thf solvate of 1:1 cocrystal of ethenzamide and 3,5-dinitrobenzoic acid
2(C9H11NO2),2(C7H4N2O6),C4H8O
Crystal Growth & Design (2010) 10, 5 2229
a=7.6358(15)Å b=8.3248(17)Å c=15.291(3)Å
α=99.50(3)° β=91.41(3)° γ=102.29(3)°
Toluene solvate of 1:1 cocrystal of ethenzamide and 3,5-dinitrobenzoic acid
C9H11NO2,C7H4N2O6
Crystal Growth & Design (2010) 10, 5 2229
a=7.5321(15)Å b=8.5532(17)Å c=16.039(3)Å
α=105.44(3)° β=92.71(3)° γ=103.57(3)°
Ethylacetate solvate of 1:1 cocrystal of ethenzamide and 3,5-dinitrobenzoic acid
C9H11NO2,C7H4N2O6
Crystal Growth & Design (2010) 10, 5 2229
a=7.6503(15)Å b=8.1921(16)Å c=15.810(3)Å
α=104.91(3)° β=92.45(3)° γ=99.99(3)°
P-xylene solvate of 1:1 cocrystal of ethenzamide and 3,5-dinitrobenzoic acid
C9H11NO2,C7H4N2O6
Crystal Growth & Design (2010) 10, 5 2229
a=7.5327(15)Å b=8.4169(17)Å c=15.847(3)Å
α=103.47(3)° β=93.06(3)° γ=101.52(3)°
Mesitylene solvate of 1:1 cocrystal of ethenzamide and 3,5-dinitrobenzoic acid
C9H11NO2,C9H12,C7H4N2O6
Crystal Growth & Design (2010) 10, 5 2229
a=7.5121(15)Å b=11.316(2)Å c=28.712(6)Å
α=90.00° β=90.68(3)° γ=90.00°
1:1 cocrystal of nitrofurantoin and urea
C8H6N4O5,CH4N2O
Crystal Growth & Design (2012) 12, 12 5925
a=6.6779(13)Å b=13.648(3)Å c=14.003(4)Å
α=90.00° β=110.95(3)° γ=90.00°